Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy

Cancer Science

Volumn 104, Issue 8, 2013, Pages 1045-1051

  Makuuchi, Yosuke ^a,b   Honda, Kazufumi ^a   Osaka, Yoshiaki ^b   Kato, Ken ^c   Kojima, Takashi ^d   Daiko, Hiroyuki ^c   Igaki, Hiroyasu ^c   Ito, Yoshinori ^d   Hoshino, Sumito ^b   Tachibana, Shingo ^b   Watanabe, Takafumi ^a,b   Furuta, Koh ^c   Sekine, Shigeki ^a   Umaki, Tomoko ^a   Watabe, Yukio ^a   Miura, Nami ^a   Ono, Masaya ^a   Tsuchida, Akihiko ^b   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; C REACTIVE PROTEIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; INSULIN; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; STAT3 PROTEIN; STROMELYSIN;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER TISSUE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LOW DRUG DOSE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; TREATMENT RESPONSE;

EID: 84881089858     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12187     Document Type: Article

References (38)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37(Suppl. 8): S4-66.
2. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-30.
3. Osaka Y, Takagi Y, Tsuchida A et al. Concurrent preoperative chemoradiotherapy for stage III or IV esophageal squamous carcinoma. Oncol Rep 2004; 12: 1121-6.
4. Lee JL, Park SI, Kim SB et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 947-54.
5. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6: 659-68.
6. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
7. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84.
8. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-7.
9. Kim MK, Kim SB, Ahn JH et al. Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2008; 71: 725-34.
10. Donahue JM, Nichols FC, Li Z et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009; 87: 392-8; discussion 8-9.
11. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007; 25: 4110-7.
12. Geh JI. The use of chemoradiotherapy in oesophageal cancer. Eur J Cancer 2002; 38: 300-13.
13. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
14. Seike M, Yanaihara N, Bowman ED et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007; 99: 1257-69.
15. Suzuki Y, Mimura K, Yoshimoto Y et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 2012; 72: 3967-76.
16. Sobin LH. TNM Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002; 99-103.
17. The Japanese Society for Esophageal Disease. Guidlines for the Clinical and Pathologic Studies on Carcinoma of the Esophagus, 9th edn. In: Isono K, ed. Tokyo: Kanehara Shuppan, 2001.
18. Kikuchi S, Honda K, Tsuda H et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008; 14: 5348-56.
19. Kojima T, Hashimoto J, Kato K et al. Feasibility study of neoadjuvant chemoradiotherapy with cisplatin plus 5-fluorouracil and elective nodal irradiation for stage II/III esophageal squamous cell carcinoma. J Clin Oncol 2012; 37(Suppl. 4): Abstract 130.
20. Honda K, Yamada T, Endo R et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998; 140: 1383-93.
21. Honda K, Yamada T, Hayashida Y et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005; 128: 51-62.
22. Honda K, Hayashida Y, Umaki T et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 2005; 65: 10613-22.
23. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996; 86: 726-8.
24. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg 2010; 14: 462-9.
25. Shimada H, Nabeya Y, Okazumi S et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003; 83: 248-52.
26. Yamaji T, Inoue M, Sasazuki S et al. Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan: the JPHC study. Int J Cancer 2008; 123: 1935-40.
27. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15: 43-58.
28. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121: 3375-83.
29. Garbers C, Thaiss W, Jones GW et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011; 286: 42959-70.
30. Oka M, Iizuka N, Yamamoto K et al. The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 1996; 16: 1001-6.
31. Fujiwara H, Suchi K, Okamura S et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol 2011; 103: 62-8.
32. Shimada H, Takeda A, Nabeya Y et al. Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001; 92: 663-9.
33. Shimada H, Kitabayashi H, Nabeya Y et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 2003; 133: 24-31.
34. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20: 198-208.
35. Suchi K, Fujiwara H, Okamura S et al. Overexpression of Interleukin-6 suppresses cisplatin-induced cytotoxicity in esophageal squamous cell carcinoma cells. Anticancer Res 2011; 31: 67-75.
36. Efimova EV, Liang H, Pitroda SP et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 2009; 85: 421-31.
37. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003; 22: 7809-18.
38. Sun Y, Moretti L, Giacalone NJ et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol 2011; 6: 699-706.